

Swedish Biomimetics 3000® AB

A V²IO® Innovation Accelerator

PRESS RELEASE

UK, January 21, 2013

Small and Micro Businesses share £1.38m Manufacturing Innovation Funding

Swedish Biomimetics 3000® are among nearly 60 small and micro businesses who will share a grant funding totalling £1.38 million from the Technology Strategy Board (www.innovateuk.org) to carry out feasibility studies that may lead to innovations in a range of manufacturing competences.

Commenting on the award, Dr. Andrew Copestake, Chief Executive Officer of Swedish Biomimetics 3000® said, "This marks a significant achievement for our ContaPep peptide manufacturing technology"

The funding awards follow the conclusion of the 'Innovation in Manufacturing Competences' competition for feasibility funding, which sought proposals for short-term feasibility studies across the whole manufacturing lifecycle, from design and engineering through to process development, manufacture, service delivery and re-manufacture/re-use, including innovation in supply/distribution chains, risk management and business models.

About Swedish Biomimetics 3000®

Swedish Biomimetics 3000® AB was founded 2004 by the Swedish entrepreneur Lars-Uno Larsson. The objective is to fund, and through its V²IO® innovation accelerating model, foster translational research and development of Biomimetics Inspired concepts until they are considered commercial candidates. Swedish Biomimetics 3000® with its corporate office in Stockholm, Sweden, has virtual offices at Medical Village in Lund, in Japan, USA, Australia and a fully owned research/development and commercial subsidiary, Swedish Biomimetics 3000® Ltd at Oxford Science Park, UK. <http://www.swedishbiomimetics3000.com>

For further information regarding Swedish Biomimetics 3000® AB:

Please contact Dr Andrew Copestake, CEO, phone +44 7545 899412.